astronomy

Liminal BioSciences

Liminal BioSciences is a astronomy topic covered in the lgStudy science library. This page brings together a partial reference excerpt, illustrations, worked examples, real-world applications and a short study plan, so you can understand Liminal BioSciences rather than just read about it. In short: Liminal BioSciences Inc., formerly known as Prometic Life Sciences Inc., is a Canadian biopharmaceutical company. History Liminal was founded in 1988, as a commercial spinoff of research at the University of Cambridge on affinity chromatography.

Key takeaways

Liminal BioSciences belongs to astronomy; place it in that map before memorising details.
Learn the definition first, then one example that makes the definition concrete.
Connect Liminal BioSciences to a quantity you can measure, compute or draw — that is where exam questions come from.
Reproduce the core statement of Liminal BioSciences from memory before moving on to harder problems.

Reference excerpt

Liminal BioSciences Inc., formerly known as Prometic Life Sciences Inc., is a Canadian biopharmaceutical company.

History Liminal was founded in 1988, as a commercial spinoff of research at the University of Cambridge on affinity chromatography. Its founder was the current President and CEO, Pierre Laurin, whose research formed the basis for the company's products. Liminal was incorporated on October 14, 1994 under the Canada Business Corporations Act, or the CBCA, under the name Innovon Life Sciences Holdings Limited. In August 2016, the company announced the acquisition of Telesta Therapeutics. It changed its name to “Prometic Life Sciences Inc.” on May 19, 1998 and subsequently rebranded to “Liminal BioSciences Inc.” on October 3, 2019. On July 28, 1998, the Company's common shares began trading on the Toronto Stock Exchange, or the TSX, under the trading symbol “PLI” and, on October 7, 2019, began trading under the trading symbol “LMNL.” On November 18, 2019, Liminal's common shares began trading on the Nasdaq Global Market, or the Nasdaq, under the trading symbol “LMNL.” On August 5, 2020, it voluntarily delisted its common shares from the TSX. On May 19, 1998, the Corporation went public through a listing on the Toronto Stock Exchange. In September 2023, the company was taken private by Thomvest Asset Management Ltd. and delisted from Nasdaq.

Business Liminal BioSciences' development programs target seven transmembrane G protein-coupled receptors (GPCRs), where the receptor protein passes through the cell membrane seven times. These receptors are easily accessible to hydrophilic drugs due to their presence on the cell surface, and their non-uniform expression enables selectivity in modulating physiological processes. Agonists and antagonists of 7TM GPCRs receptors are utilized for treating various diseases in all organ systems. An agonist is a drug that binds to a target and mimics the action of the natural ligand. An antagonist is a drug that binds to a receptor and prevents other molecules (such as the natural ligand) from binding. Liminal BioSicences' drug discovery platform leverages fully integrated chemistry and biology expertise supported by broad in-vivo capabilities, allowing it to investigate preclinical drug candidates’ efficacy based on a wide variety of animal models, enabling the development of small-molecule therapeutic candidates for the treatment of various metabolic, inflammatory and fibrotic diseases. Liminal BioSciences is a development stage biopharmaceutical company focused on discovering and developing novel and distinctive small molecule therapeutics that modulate G protein-coupled receptors, or GPCR, pathways. The Company is designing proprietary novel small molecule therapeutic candidates with the intent of developing therapeutics for the treatment of metabolic, inflammatory and fibrotic diseases with significant unmet medical needs. Liminal BioSciences' pipeline is currently made up of three development programs. The candidate selected for clinical development, LMNL6511, a selective antagonist for the GPR84, is expected to commence a Phase 1 clinical trial in the second half of 2023. The Company is also developing potential OXER1 antagonists and FFAR1 (GPR40) agonists, both of which are at the preclinical stage. In addition to these priority development programs.

Controversies From early 2018 to early 2019, Prometic Life Sciences' Share price dropped 79%. The company's sought permission from the Toronto Stock Exchange to proceed without a shareholder vote for reasons of "financial hardship". In October 2019, the company allowed its shareholders to vote on a name change.

References

External links Official website

Worked examples

Example 1 — a first encounter with Liminal BioSciences

Start with the simplest possible case. Write down what Liminal BioSciences claims or describes in one sentence, then invent the smallest concrete situation in which that sentence is true. In astronomy, the smallest case is usually a single object, a single equation or a single measurement. Check that every symbol or term in your sentence has a meaning in that case.

Example 2 — changing one variable

Take the situation from Example 1 and change exactly one quantity: double it, halve it, or set it to zero. Predict what should happen to Liminal BioSciences before you calculate. Comparing your prediction with the result is the fastest way to find out whether you understand the idea or only the words.

Example 3 — an exam-style question

Typical questions about Liminal BioSciences ask you to (a) state it precisely, (b) apply it to given data, and (c) explain a limitation. Practise writing all three answers in under five minutes; the third part is what separates a full-mark answer from an average one.

Applications of Liminal BioSciences

In research: Liminal BioSciences appears in astronomy research whenever the underlying quantities have to be modelled precisely. Papers usually cite it as a starting assumption and then explore where it breaks down.
In technology and industry: Engineering practice reuses Liminal BioSciences in design rules, simulations and safety margins. Knowing the idea lets you read a specification sheet and understand why the numbers look the way they do.
In the classroom: Liminal BioSciences is common in secondary-school and first-year university syllabi. It links to neighbouring topics Companies based in Laval, Quebec, Companies formerly listed on the Nasdaq, Companies formerly listed on the Toronto Stock Exchange, so understanding it makes those chapters shorter.
In everyday life: Look for Liminal BioSciences outside the textbook — in sport, cooking, traffic, electronics or the sky above you. An example you found yourself is remembered far longer than one you were given.

Affiliate

Preply — study more efficiently by working with a personal tutor. 50% off.

How to study Liminal BioSciences in 20 minutes

Read the reference excerpt below once, without taking notes.
Close the page and write down what Liminal BioSciences means in your own words.
Compare your version with the excerpt and mark what you missed.
Work through the three examples above with pen and paper.
Explain Liminal BioSciences out loud to somebody else — or to Teacher Smith in the lgStudy chat.

Frequently asked questions

What is Liminal BioSciences in simple terms?

Liminal BioSciences Inc., formerly known as Prometic Life Sciences Inc., is a Canadian biopharmaceutical company. History Liminal was founded in 1988, as a commercial spinoff of research at the University of Cambridge on affinity chromatography.

Why does Liminal BioSciences matter?

Because it connects several astronomy ideas at once: it gives you a definition you can apply, a quantity you can calculate, and a way to check whether a result is plausible.

How should I study Liminal BioSciences?

Read the excerpt, restate it from memory, then work through the examples and applications listed on this page. The five-step study plan above takes about twenty minutes.

What does this page cover?

It gives you a compact reference excerpt plus original lgStudy explanations, examples, applications and study material on Liminal BioSciences.